[Expected to Become the First FDA-Approved Autism Treatment Drug, Yamo Pharma's L1-79 Enters Phase II Clinical Trials] Odaily Planet Daily News: Bloomberg ETF analyst Eric Balchunas posted on the X platform, quoting Defiance CEO and ASD issuer Matt Bielski, who stated that Yamo Pharma's L1-79 has 'changed lives.' His 4-year-old son Lev suffers from severe autism. L1-79 is currently in Phase II clinical trials and is expected to become the first FDA-approved treatment for autism. In the U.S., approximately 1 in 31 children is diagnosed with autism, including Bielski's youngest son.